National Health Service

Sky-high waiting times don’t make people trust the NHS any less – why that’s potentially bad news for Rishi Sunak

Retrieved on: 
Thursday, April 18, 2024
Culture, Democracy, NHS, Walking, Trust, COVID-19, National Health Service, Research, History, Life, Conservatism, Survation, Labour, Government, Police, Health insurance

Waiting times in accident and emergency and referral times for specialist treatment remain staggeringly high.

Key Points: 
  • Waiting times in accident and emergency and referral times for specialist treatment remain staggeringly high.
  • As researchers on trust, this led us to a question: do high waiting times mean people trust the NHS less?
  • Trust is hugely important to society, as it tells us so much about people’s faith in the integrity of institutions.
  • On a seven-point scale, trust in the NHS was a full two points higher than trust in parliament.

NanoVibronix Issues Letter to Stockholders

Retrieved on: 
Tuesday, April 9, 2024
Medical Devices, Health, Health Technology, Research, Science, Biotechnology, National Health Service, Growth, Partnership, COVID-19, Patient, SAW, Gold, NHS, University, University of Michigan, Quality of life, Insurance, GSA, Urinary tract infection, Pain, Medicare, FDA, CMS, Engineering, Food, Pharmaceutical industry

We are focused on several areas that we believe will have a substantial impact on our growth and product adoption.

Key Points: 
  • We are focused on several areas that we believe will have a substantial impact on our growth and product adoption.
  • A driving factor in our increased revenues was increased sales to customers using the Veterans’ Health System and worker’s compensation plans.
  • On our balance sheet for the period ended December 31, 2023, we had $3.3 million of cash and inventory of $2.7 million.
  • CMS invited NanoVibronix to a public meeting to present its findings and to answer CMS’s questions, which was held June 1, 2023.

Nanox Announces AI Software Increases Identification of Patients with Vertebral Compression Fractures, an early sign of Osteoporosis, Up to Six-Fold

Retrieved on: 
Tuesday, March 12, 2024
Syndrome, Health, National Health Service, ROI, Congress, LTD, Rheumatology, Bone disease, Data analysis, Risk, Patient, Fracture, VCF, NHS, Abdomen, Hospital, Research, AI, University, Systematic review, Treatment, Spine, FLS, Family, FDA, Vertebral compression fracture, University of Oxford, Medical device

PETACH TIKVA, Israel, March 12, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, and its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd. (Nanox.AI), today announced that early findings from the AI-enabled Detection of OsteoPorosis for Treatment (ADOPT) study, which uses a Nanox.AI artificial intelligence solution, HealthVCF, to review routine CT scans, have identified up to six times more patients with vertebral compression fracture than the national average at National Health Services (NHS) hospitals in the UK, which include University of Oxford and other healthcare centers.

Key Points: 
  • Thus far in the study, the Nanox.AI algorithm has identified over 2,400 patients with VCF from routine CT scans that were not known to the NHS’s hospitals, and have since been flagged for follow-up assessments.
  • “Leveraging AI-powered population health solutions presents an effective and efficient avenue for early identification of patients at very high risk of fractures, facilitating timely intervention and care.
  • As such, there have been efforts to introduce FLS into public health systems.
  • The next-generation HealthOST received FDA 510(K) clearance in April 2022.

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Diagnosis, De novo, PIN, Obesity, MRI, Syndrome, Metabolism, KCH, Knowledge Organization (journal), International, National Health Service, NHS, Research, Radiology, MASH, Trial of the century, International Classification of Diseases, Hepatology, World Health Organization, Data collection, Prediabetes, NDRA, Liver, Type 2 diabetes, Liver disease, Marketing, NAFLD, Endocrinology, Video game

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.
  • Highlights from the fourth quarter of 2023 and recent weeks include:
    Installed first TAEUS system in the UK at King’s College Hospital for clinical evaluation.
  • In the third quarter of 2023, ENDRA submitted a De Novo request for its TAEUS liver system to the FDA.
  • In the fourth quarter of 2023, the FDA issued an Additional Information (AI) request to ENDRA.

Hyperfine, Inc. Collaborates with King’s College London to Demonstrate the Swoop® System and UNITY Project to The Princess Royal

Retrieved on: 
Tuesday, March 12, 2024
Research, Medical Devices, Neurology, Hospitals, Health Technology, Radiology, Health, General Health, Science, Mother, HRH, Princess Royal, Brain, King, MRI, Bill, Hyperfine structure, National Health Service, NHS, Ultra, Quality of life, King's College London, Multimedia, Royal Highness, FDA, School, Medical imaging

Her Royal Highness was shown a demonstration of the Swoop® system to see first-hand the device’s ease of use.

Key Points: 
  • Her Royal Highness was shown a demonstration of the Swoop® system to see first-hand the device’s ease of use.
  • “It is a great pleasure for us to introduce HRH Princess Royal to the UNITY project.
  • “Since 2021, the Hyperfine, Inc. collaboration with King’s College London has further enabled our vision of making brain MRI accessible anywhere in the world to become a reality at UNITY project sites,” said Ms. Sainz.
  • The center also provides National Health Service (NHS) services under the South London and Maudsley NHS Foundation Trust.

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

Retrieved on: 
Tuesday, March 12, 2024
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, EAMS, Patient, HAE, National Health Service, Health care, NHS, American Academy, KALV, Expanded access, Marketing, MHRA, PIM, Hereditary angioedema, Safety, AAAAI, Pharmaceutical industry

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Promising Innovative Medicine (PIM) designation for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE).

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Promising Innovative Medicine (PIM) designation for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE).
  • The PIM is the first step in the Early Access to Medicines Scheme (EAMS) which would allow KalVista to treat patients with sebetralstat prior to receiving a Marketing Authorisation.
  • “We are proud to have sebetralstat designated as a Promising Innovative Medicine by the MHRA, which is similar to Expanded Access in the US,” said Ben Palleiko, Chief Executive Officer of KalVista.
  • KalVista recently provided phase 3 data for sebetralstat at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, which displayed clinically and statistically significant results across all endpoints, and an excellent safety and tolerability profile.

commercetools Accelerates Global Momentum, Announces Strong 2023 Business Results

Retrieved on: 
Tuesday, March 26, 2024
Black Friday, Organization, Software as a service, ARR, Growth, Insight Partners, Risk, Connect, National Health Service, Digital, NHS, News, Ticketmaster, B2C, Elevate, Record, Bausch & Lomb, Yoy, PetSmart, Fortune 500, GMV, Commerce, B2B, Commercetools, Cyber Monday, European, Magic Quadrant, Management

2023 was a standout year for commercetools.

Key Points: 
  • 2023 was a standout year for commercetools.
  • Our robust business momentum and fiscal results are evidence of the value customers find in commercetools and composable commerce," said Dirk Hoerig, co-founder and CEO of commercetools.
  • Customer base is now equally split across EMEA and the Americas, solidifying commercetools' global expansion and underscoring the company's strong foothold in the American market as a European SaaS company.
  • In the last 18 months, the company announced six new products, including commercetools Connect , commercetools Checkout and commercetools Foundry , making it easier than ever to infuse composability into the modern commerce stack.

XRP Healthcare Partner with NHS collaborator Isansys Lifecare to Revolutionize Healthcare Services in Uganda

Retrieved on: 
Monday, March 25, 2024
XRP, DHL, Partnership, Patient, Pharmacy, National Health Service, NHS, Health care, Hospital, Research, Acquisition, NASA, Safety, RPM, Health

DUBAI, UAE, March 25, 2024 /PRNewswire/ -- XRP Healthcare is thrilled to announce a strategic partnership with Isansys Lifecare, a leading innovator in the digital healthcare technology sector, to enhance healthcare infrastructure and services across Uganda.

Key Points: 
  • DUBAI, UAE, March 25, 2024 /PRNewswire/ -- XRP Healthcare is thrilled to announce a strategic partnership with Isansys Lifecare, a leading innovator in the digital healthcare technology sector, to enhance healthcare infrastructure and services across Uganda.
  • Keith Errey, CEO of Isansys Lifecare, commented "We are excited to partner with XRP Healthcare to bring cutting-edge healthcare technology to its private healthcare facilities in Uganda.
  • Whitney Lynn, Chairman of XRP Healthcare stated, "This partnership with Isansys Lifecare represents a significant milestone in our mission to enhance healthcare services in Uganda.
  • CEO of XRP Healthcare Kain Roomes said, " I am more than pleased to announce our partnership with Isansys Lifecare, a collaboration that promises to revolutionize healthcare delivery in Uganda.

XRP Healthcare Partner with NHS collaborator Isansys Lifecare to Revolutionize Healthcare Services in Uganda

Retrieved on: 
Monday, March 25, 2024
XRP, DHL, Partnership, Patient, Pharmacy, National Health Service, NHS, Health care, Hospital, Research, Acquisition, NASA, Safety, RPM, Health

DUBAI, UAE, March 25, 2024 /PRNewswire/ -- XRP Healthcare is thrilled to announce a strategic partnership with Isansys Lifecare, a leading innovator in the digital healthcare technology sector, to enhance healthcare infrastructure and services across Uganda.

Key Points: 
  • DUBAI, UAE, March 25, 2024 /PRNewswire/ -- XRP Healthcare is thrilled to announce a strategic partnership with Isansys Lifecare, a leading innovator in the digital healthcare technology sector, to enhance healthcare infrastructure and services across Uganda.
  • Keith Errey, CEO of Isansys Lifecare, commented "We are excited to partner with XRP Healthcare to bring cutting-edge healthcare technology to its private healthcare facilities in Uganda.
  • Whitney Lynn, Chairman of XRP Healthcare stated, "This partnership with Isansys Lifecare represents a significant milestone in our mission to enhance healthcare services in Uganda.
  • CEO of XRP Healthcare Kain Roomes said, " I am more than pleased to announce our partnership with Isansys Lifecare, a collaboration that promises to revolutionize healthcare delivery in Uganda.

Heart & Lung Health selects Caristo Diagnostics AI technology to provide early diagnosis of coronary artery disease UK-wide

Retrieved on: 
Tuesday, March 19, 2024
Diagnosis, Lung cancer, Chest pain, Information technology, Radiology, Coronary artery disease, Partnership, Risk, University, Patient, Lung, Calcium, National Health Service, NHS, Research, Hospital, RadNet, Artificial intelligence, Death, Plaque, Artery, Mace, CCTA, Heart, HLH, Health, Medical device

OXFORD, England, March 19, 2024 /PRNewswire/ -- Heart & Lung Health (HLH), a UK-wide network of over 110 expert cardiothoracic radiologists, has partnered with Caristo Diagnostics, a leading cardiac disease diagnostics company, to offer the novel CaRi-Heart® AI technology to predict patients' risk of developing potentially fatal coronary artery disease.

Key Points: 
  • OXFORD, England, March 19, 2024 /PRNewswire/ -- Heart & Lung Health (HLH) , a UK-wide network of over 110 expert cardiothoracic radiologists, has partnered with Caristo Diagnostics , a leading cardiac disease diagnostics company, to offer the novel CaRi-Heart® AI technology to predict patients' risk of developing potentially fatal coronary artery disease.
  • Many will undergo a coronary computed tomography angiography (CCTA) scan to diagnose coronary artery disease caused by plaques that narrow or block the arteries that supply blood to the heart.
  • "Early diagnosis and interventions have the potential to significantly improve health outcomes for thousands of patients at risk of coronary artery disease.
  • We are pleased to announce our partnership with Heart & Lung Health, aiming to enhance accessibility to CaRi-Heart technology for patients throughout the UK," said Frank Cheng, CEO of Caristo Diagnostics.